Safety of First-Line Nivolumab Plus Ipilimumab in Very Old (≥ 80 Years) Patients With Unresectable Malignant Pleural Mesothelioma: A Retrospective Single-Center Case Series

被引：0
|
作者：
Shimamoto, Takayuki [1 ]
Morimoto, Yoshie [1 ]
Nitta, Naohiro [1 ]
Yoshida, Rie [1 ]
Tani, Nozomi [1 ]
机构：
[1] Kyoto Kuramaguchi Med Ctr, Dept Pulm Med, Kyoto, Japan
来源：
CUREUS JOURNAL OF MEDICAL SCIENCE | 2024年 / 16卷 / 01期
关键词：
safety; case series; age; malignant pleural mesothelioma; nivolumab plus ipilimumab; CELL LUNG-CANCER; ELDERLY-PATIENTS;
D O I：
10.7759/cureus.52714
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Nivolumab plus ipilimumab as the first -line treatment results in superior survival outcomes in patients with malignant pleural mesothelioma (MPM). However, its safety in old (>= 80 years) patients with MPM has not been elucidated yet. Three male patients with MPM, aged 80-90 years, were treated with nivolumab plus ipilimumab as the first -line treatment in our hospital. All of them discontinued the treatment due to adverse events. The overall survival from treatment initiation was 2.5, 3.5, and 4.0 months, respectively. Nivolumab plus ipilimumab should be used cautiously in very old patients with MPM.
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
    Barbier, Michaela Carla
    Fengler, Alicia
    Pardo, Esther
    Bhadhuri, Arjun
    Meier, Niklaus
    Gautschi, Oliver
    PHARMACOECONOMICS, 2023, 41 (12) : 1641 - 1655
  • [22] Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
    Michaela Carla Barbier
    Alicia Fengler
    Esther Pardo
    Arjun Bhadhuri
    Niklaus Meier
    Oliver Gautschi
    PharmacoEconomics, 2023, 41 : 1641 - 1655
  • [23] A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol
    Fujimoto, Nobukazu
    Aoe, Keisuke
    Kozuki, Toshiyuki
    Oze, Isao
    Kato, Katsuya
    Kishimoto, Takumi
    Hotta, Katsuyuki
    CLINICAL LUNG CANCER, 2018, 19 (05) : E705 - E707
  • [24] A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: JME-001
    Fujimoto, N.
    Kozuki, T.
    Aoe, K.
    Miyamoto, Y.
    Wada, S.
    Harada, D.
    Yoshida, M.
    Sakurai, J.
    Hotta, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1077 - S1077
  • [25] JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
    Miyamoto, Yosuke
    Kozuki, Toshiyuki
    Aoe, Keisuke
    Wada, Sae
    Harada, Daijiro
    Yoshida, Michihiro
    Sakurai, Jun
    Hotta, Katsuyuki
    Fujimoto, Nobukazu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
  • [26] Editorial Comment to Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study
    Tamada, Satoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (12) : 1100 - 1101
  • [27] Carboplatin Plus Pemetrexed as First-line Treatment of Patients With Malignant Pleural Mesothelioma: A Phase II Study
    Katirtzoglou, Nikolaos
    Gkiozos, Ioannis
    Makrilia, Nektaria
    Tsaroucha, Emilia
    Rapti, Aggeliki
    Stratakos, Grigorios
    Fountzilas, Georgios
    Syrigos, Konstantinos N.
    CLINICAL LUNG CANCER, 2010, 11 (01) : 30 - 35
  • [28] Docetaxel plus Gemcitabine as First-line Treatment in Malignant Pleural Mesothelioma: A Single Institution Phase II Study
    Ralli, Maria
    Tourkantonis, Ioannis
    Makrilia, Nektaria
    Gkini, Eleni
    Kotteas, Elias
    Gkiozos, Ioannis
    Katirtzoglou, Nikolaos
    Syrigos, Kostas
    ANTICANCER RESEARCH, 2009, 29 (08) : 3441 - 3444
  • [29] RETROSPECTIVE ANALYSIS OF CLINICOPATHOLOGIC AND SURVIVAL DATA OF MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS IN A SINGLE CENTER SERIES
    Cedres Perez, S.
    Martinez Marti, A.
    Martinez Rodriguez, P.
    Torrejon Castro, D.
    Sullivan, I.
    Pallisa, E.
    Murtra, N.
    Montero, M. A.
    Hernandez, J.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S84 - S85
  • [30] Checkmate 743: A phase 3 randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.
    Zalcman, Gerard
    Peters, Solange
    Mansfield, Aaron Scott
    Jahan, Thierry Marie
    Popat, Sanjay
    Scherpereel, Arnaud
    Hu, Wenhua
    Selvaggi, Giovanni
    Baas, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345